TipRanks
NervGen Pharma (DE:9UA)
FRANKFURT:9UA
Germany Market
9UA
NervGen Pharma
RESEARCH TOOLSreports

NervGen Pharma (9UA) Income Statement

3 Followers

NervGen Pharma Income Statement

Last quarter (Q2 2026), NervGen Pharma's total revenue was C$0.00, a decrease of ― from the same quarter last year. In Q2, NervGen Pharma's net income was C$-29.99M. See NervGen Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Mar 26Mar 25Mar 24Dec 22Dec 21
Total Revenue
C$ 0.00C$ 0.00C$ 0.00C$ 0.00C$ 0.00
Gross Profit
C$ 0.00C$ -83.74KC$ -145.01KC$ -114.10KC$ -42.95K
Operating Expenses
C$ 25.08MC$ 24.83MC$ 17.63MC$ 22.71MC$ 12.87M
Depreciation and Amortization
C$ 55.80KC$ 83.74KC$ 145.01KC$ 114.10KC$ 42.95K
EBITDA
C$ -5.65MC$ -23.91MC$ -22.24MC$ -19.92MC$ -12.78M
Operating Income
C$ -25.08MC$ -24.92MC$ -17.78MC$ -22.82MC$ -12.91M
Other Income/Expenses
C$ -19.04MC$ 925.48K-C$ 2.28MC$ 85.29K
Pretax Income
C$ -44.12MC$ -23.99MC$ -22.38MC$ -20.54MC$ -12.82M
Net Income
C$ -44.12MC$ -23.99MC$ -22.38MC$ -20.54MC$ -12.82M
Per Share Metrics
Basic EPS
C$ -0.61C$ -0.36C$ -0.37C$ -0.39C$ -0.33
Diluted EPS
C$ -0.61C$ -0.36C$ -0.37C$ -0.39C$ -0.33
Weighted Average Shares Outstanding
 72.33M 67.32M 59.29M 52.65M 39.29M
Weighted Average Shares Outstanding (Diluted)
 72.33M 67.32M 59.29M 52.65M 39.29M
Currency in CAD

NervGen Pharma Earnings and Revenue History